The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

Understanding and controlling the spread of antimalarial resistance, particularly to
artemisinin and its partner drugs, is a top priority. Plasmodium falciparum parasites resistant …

Malaria parasites break down host haemoglobin into peptides and amino acids in the
digestive vacuole for export to the parasite cytoplasm for growth: interrupting this process is …

Highlights•Mutant K13-mediated artemisinin resistance involves reduced hemoglobin
endocytosis.•Artemisinin partial resistance has emerged in Africa.•Novel PfCRT mutations …

The widely used antimalarial combination therapy dihydroartemisinin+ piperaquine (DHA+
PPQ) has failed in Cambodia. Here, we perform a genomic analysis that reveals a rapid …

Antimalarial drug resistance has historically arisen through convergent de novo mutations in
Plasmodium falciparum parasite populations in Southeast Asia and South America. For the …

Antimalarial chemotherapy, globally reliant on artemisinin-based combination therapies
(ACTs), is threatened by the spread of drug resistance in Plasmodium falciparum parasites …

The emergence and spread of drug-resistant Plasmodium falciparum impedes global efforts
to control and eliminate malaria. For decades, treatment of malaria has relied on …

Chemogenetic characterization through in vitro evolution combined with whole-genome
analysis can identify antimalarial drug targets and drug-resistance genes. We performed a …